S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.06 (-1.72%)
MSFT   312.39 (-1.62%)
META   299.20 (-0.54%)
GOOGL   128.33 (-2.12%)
AMZN   127.94 (-2.54%)
TSLA   247.50 (+0.21%)
NVDA   422.80 (+0.14%)
NIO   8.50 (+1.80%)
BABA   86.21 (-1.16%)
AMD   96.20 (-1.21%)
T   15.06 (+0.00%)
F   12.55 (-0.24%)
MU   68.29 (-0.42%)
CGC   0.93 (-1.27%)
GE   110.23 (-1.33%)
DIS   80.53 (-0.59%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.13 (+0.46%)
NFLX   381.66 (-0.82%)
OTCMKTS:HCYTD

H-CYTE (HCYTD) Stock Forecast, Price & News

$2.02
-1.98 (-49.50%)
(As of 07/11/2022)
Compare
Today's Range
$2.02
$2.77
50-Day Range
$2.02
$2.02
52-Week Range
$2.02
$77.00
Volume
400 shs
Average Volume
103 shs
Market Capitalization
$521,160.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HCYTD stock logo

About H-CYTE (OTCMKTS:HCYTD) Stock

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

HCYTD Price History

HCYTD Stock News Headlines

H-E-B Grocery Company
10-K: H-CYTE, INC.
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
HCYT H-CYTE, Inc.
H-CYTE Completes Acquisition of Jantibody
H-CYTE Announces 1-for-1,000 Reverse Stock Split
Should You Refrigerate Peanut Butter?
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
H-CYTE Inc (HCYT)
H-CYTE Names Michael Yurkowsky Chief Executive Officer
Scanfil plc: Managers' transactions – Jokitalo
Robert Greif named Chief Executive Officer of H-CYTE
See More Headlines
Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Company Calendar

Today
9/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HCYTD
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-4,800,000.00
Net Margins
-450.40%
Pretax Margin
-450.40%

Debt

Sales & Book Value

Annual Sales
$1.61 million
Book Value
($31.45) per share

Miscellaneous

Free Float
244,000
Market Cap
$521,160.00
Optionable
Not Optionable
Beta
1.12
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael W. Yurkowsky (Age 50)
    CEO & Director
    Comp: $180k
  • Mr. Jeremy Daniel (Age 46)
    Chief Financial Officer
    Comp: $200k
  • Dr. Tanya Rhodes Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $252k
  • Mr. Jeffery Wright CPA (Age 39)
    CPA, Controller & Principal Accounting Officer













HCYTD Stock - Frequently Asked Questions

How have HCYTD shares performed in 2023?

H-CYTE's stock was trading at $2.02 at the start of the year. Since then, HCYTD stock has increased by 0.0% and is now trading at $2.02.
View the best growth stocks for 2023 here
.

What is H-CYTE's stock symbol?

H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD."

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is H-CYTE's stock price today?

One share of HCYTD stock can currently be purchased for approximately $2.02.

How much money does H-CYTE make?

H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year.

How can I contact H-CYTE?

H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com.

This page (OTCMKTS:HCYTD) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -